The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report.
 
Michael B. Atkins
Stock and Other Ownership Interests - Pyxis; Werewolf Pharma
Consulting or Advisory Role - Adagene; Agenus; Arrowhead Pharmaceuticals; Asher Biotherapeutics; AstraZeneca; Aveo; Bristol-Myers Squibb; Calithera Biosciences; Cota Healthcare; Eisai; Ellipses Pharma; Exelixis; Fathom Biotechnology; Genentech; Idera; Iovance Biotherapeutics; Leads Biolabs; Merck; Neoleukin Therapeutics; Novartis; PACT Pharma; Pfizer; Pneuma Respiratory; Pyxis; Sanofi; Scholar Rock; Seagen; Simcha Therapeutics; Surface Oncology; Takeda; Werewolf Pharma
Research Funding - Bristol-Myers Squibb (Inst)
 
Opeyemi Jegede
No Relationships to Disclose
 
Naomi B. Haas
Consulting or Advisory Role - AVEO; Calithera Biosciences; Eisai; Exelixis; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Expert Testimony - Lilly (I)
 
David F. McDermott
Consulting or Advisory Role - alkermes; Array BioPharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; exelixis; Genentech/Roche; Iovance Biotherapeutics; Jounce Therapeutics; Lilly; Merck; Novartis; Peloton Therapeutics; Pfizer
Research Funding - alkermes (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Prometheus (Inst)
Other Relationship - Beth Israel Deaconess Medical Center
(OPTIONAL) Uncompensated Relationships - AVEO; X4 Pharma
 
Mehmet Asim Bilen
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Exelixis; Genomic Health; Janssen; Nektar; Pfizer; Sanofi; Seagen
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genentech/Roche (Inst); Genome & Company (Inst); Incyte (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Seagen (Inst); Tricon Pharmaceuticals (Inst); Xencor (Inst)
 
Mark N. Stein
Consulting or Advisory Role - Exelixis; Exelixis; Janssen Oncology; Merck Sharp & Dohme; Oxford Oncology; Xencor
Research Funding - Advaxis (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Genocea Biosciences (Inst); Harpoon (Inst); Janssen Oncology (Inst); Lilly (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Nektar (Inst); Oncoceutics (Inst); Seagen (Inst); Suzhou Kintor Pharmaceuticals (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst)
 
Jeffrey Alan Sosman
Honoraria - Apexian Pharmaceuticals; Array BioPharma; Bristol-Myers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals
Consulting or Advisory Role - Apexigen; Array BioPharma; Bristol-Myers Squibb; Iovance Biotherapeutics; Jazz Pharmaceuticals
 
Robert S. Alter
Consulting or Advisory Role - Bayer; Eisai; Janssen Biotech
Speakers' Bureau - Astellas Pharma; Aveo; Bayer; Bristol-Myers Squibb; Exelixis; Gilead Sciences; Janssen Oncology; Pfizer
 
Elizabeth R. Plimack
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Flatiron Health; Genentech/Roche; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; Pfizer; Seagen
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst)
 
Moshe Chaim Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Exelixis
 
Michael E. Hurwitz
Employment - Arvinas (I); Gamida Cell (I); Pfizer (I)
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene; crispr therapeutics; Exelixis; Janssen; Nektar
Research Funding - Achilles Therapeutics; Apexigen; Astellas Pharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Endocyte; Endocyte; Genentech; Genmab; Innocrin Pharma; Iovance Biotherapeutics; Lilly; Merck; Nektar; Novartis; Novartis; Pfizer; Progenics; Sanofi/Aventis; Seagen; Torque; Unum Therapeutics
 
David J. Peace
Stock and Other Ownership Interests - Bristol-Myers Squibb; Merck
Patents, Royalties, Other Intellectual Property - U.S. Patent # 8,557,777 B2: Methods of Treating Prostate Cancer Using Prostate Specific Antigen and Tumor Endothelial Marker Peptides. October 15, 2013. (Inst)
 
Sabina Signoretti
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb Foundation; Crispr Therapeutics; Merck
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Biogenex
 
Thomas Denize
No Relationships to Disclose
 
Alessia Cimadamore
Honoraria - AstraZeneca/Merck
 
David A. Braun
Honoraria - LM Education/Exchange Service
Consulting or Advisory Role - Adept Field Solutions; Blueprint Partnership; Bristol-Myers Squibb; Charles River Associates; Dedham Group; Defined Health; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Trinity Group
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Catherine J. Wu
Stock and Other Ownership Interests - BioNTech
Research Funding - Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - BioNTech
 
David Johnson Einstein
Honoraria - OncLive
Research Funding - Bristol-Myers Squibb (Inst); Cardiff Oncology (Inst); Foundation Medicine (Inst); Puma Biotechnology (Inst)
 
Paul J. Catalano
Research Funding - Celgene (Inst)
 
Hans J. Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - aravive (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer